Efficacy of skin and nasal povidone-iodine preparation against mupirocin-resistant methicillin-resistant Staphylococcus aureus and S. aureus within the anterior nares

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 5, 2015, Pages 2765-2773

  Anderson, Michele J ^a   David, Maren L ^b   Scholz, Matt ^b   Bull, Sally J ^b   Morse, Dan ^b   Hulse Stevens, Michelle ^b   Peterson, Marnie L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN; PHOSPHATE BUFFERED SALINE; POVIDONE IODINE; PSEUDOMONIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL LOAD; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DISINFECTION; DRUG EFFICACY; EX VIVO STUDY; EXPLANT; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUCOCILIARY CLEARANCE; NONHUMAN; NOSE; NOSE SMEAR; PORCINE MODEL; PRIORITY JOURNAL; STRATUM CORNEUM; VAGINA MUCOSA; ANIMAL; CLINICAL TRIAL; DRUG EFFECTS; IN VITRO STUDY; MICROBIOLOGY; PATHOGENICITY; PIG; SKIN;

ANIMALS; HUMANS; IN VITRO TECHNIQUES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MUPIROCIN; NOSE; POVIDONE-IODINE; SKIN; SWINE;

EID: 84929915527     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04624-14     Document Type: Article

References (64)

1. Sader HS, Streit JM, Fritsche TR, Jones RN. 2006. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 12:844-852. http://dx.doi.org/10.1111/j.1469-0691.2006.01550.x.
2. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. 1999. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 20:250-280. http://dx.doi.org/10.1086/501620.
3. Owens CD, Stoessel K. 2008. Surgical site infections: epidemiology, microbiology and prevention. J Hosp Infect 70(Suppl 2):3-10. http://dx.doi.org/10.1016/S0195-6701(08)60017-1.
4. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29:996-1011. http://dx.doi.org/10.1086/591861.
5. Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y, Sloane R, Sexton DJ. 2009. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PLoS One 4:e8305. http://dx.doi.org/10.1371/journal.pone.0008305.
6. Whitehouse JD, Friedman ND, Kirkland KB, Richardson WJ, Sexton DJ. 2002. The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol 23:183-189. http://dx.doi.org/10.1086/502033.
7. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, Keohane C, Denham CR, Bates DW. 2013. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 173:2039-2046. http://dx.doi.org/10.1001/jamainternmed.2013.9763.
8. Ringberg H, Petersson AC, Walder M, Johansson PJH. 2006. The throat: an important site for MRSA colonization. Scand J Infect Dis 38:888-893. http://dx.doi.org/10.1080/00365540600740546.
9. Rimland D, Roberson B. 1986. Gastrointestinal carriage of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 24:137-138.
10. Beigi R, Hanrahan J. 2007. Staphylococcus aureus and MRSA colonization rates among gravidas admitted to labor and delivery: a pilot study. Infect Dis Obstet Gynecol 2007:70876. http://dx.doi.org/10.1155/2007/70876.
11. Kluytmans JA, Mouton JW, Ijzerman EP, Vandenbroucke-Grauls CM, Maat AW, Wagenvoort JH, Verbrugh HA. 1995. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 171:216-219. http://dx.doi.org/10.1093/infdis/171.1.216.
12. Kalmeijer MD, van Nieuwland-Bollen E, Bogaers-Hofman D, de Baere GA. 2000. Nasal carriage of Staphylococcus aureus is a major risk factor for surgical-site infections in orthopedic surgery. Infect Control Hosp Epidemiol 21:319-323. http://dx.doi.org/10.1086/501763.
13. Levy PY, Ollivier M, Drancourt M, Raoult D, Argenson JN. 2013. Relation between nasal carriage of Staphylococcus aureus and surgical site infection in orthopedic surgery: the role of nasal contamination. A systematic literature review and meta-analysis. Orthop Traumatol Surg Res 99:645-651. http://dx.doi.org/10.1016/j.otsr.2013.03.030.
14. van Rijen M, Bonten M, Wenzel R, Kluytmans J. 2008. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008:CD006216. http://dx.doi.org/10.1002/14651858.CD006216.pub2.
15. Mehta MS, Hacek DM, Kufner BA, Price C, Peterson LR. 2013. Dose-ranging study to assess the application of intranasal 2% mupirocin calcium ointment to eradicate Staphylococcus aureus nasal colonization. Surg Infect (Larchmt) 14:69-72. http://dx.doi.org/10.1089/sur.2012.086.
16. Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ. 2009. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 48:922-930. http://dx.doi.org/10.1086/597291.
17. Yano M, Doki Y, Inoue M, Tsujinaka T, Shiozaki H, Monden M. 2000. Preoperative intranasal mupirocin ointment significantly reduces postoperative infection with Staphylococcus aureus in patients undergoing upper gastrointestinal surgery. Surg Today 30:16-21. http://dx.doi.org/10.1007/PL00010040.
18. Cimochowski GE, Harostock MD, Brown R, Bernardi M, Alonzo N, Coyle K. 2001. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg 71:1572-1579. http://dx.doi.org/10.1016/S0003-4975(01)02519-X.
19. Kluytmans JA, Mouton JW, VandenBergh MF, Manders MJ, Maat AP, Wagenvoort JH, Michel MF, Verbrugh HA. 1996. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 17:780-785. http://dx.doi.org/10.1086/647236.
20. Perl TM. 2003. Prevention of Staphylococcus aureus infections among surgical patients: beyond traditional perioperative prophylaxis. Surgery 134:S10-S17. http://dx.doi.org/10.1016/S0039-6060(03)00391-X.
21. Konvalinka A, Errett L, Fong IW. 2006. Impact of treating Staphylococcus aureus nasal carriers on wound infections in cardiac surgery. J Hosp Infect 64:162-168. http://dx.doi.org/10.1016/j.jhin.2006.06.010.
22. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, Twombley J, French PP, Herwaldt LA. 2002. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 346:1871-1877. http://dx.doi.org/10.1056/NEJMoa003069.
23. Schmid H, Romanos A, Schiffl H, Lederer SR. 2013. Persistent nasal methicillin-resistant Staphylococcus aureus carriage in hemodialysis outpatients: a predictor of worse outcome. BMC Nephrol 14:93. http://dx.doi.org/10.1186/1471-2369-14-93.
24. Caffrey AR, Woodmansee SB, Crandall N, Tibert C, Fielding C, Mikolich DJ, Vezeridis MP, LaPlante KL. 2011. Low adherence to outpatient preoperative methicillin-resistant Staphylococcus aureus decolonization therapy. Infect Control Hosp Epidemiol 32:930-932. http://dx.doi.org/10.1086/661787.
25. Vasquez JE, Walker ES, Franzus BW, Overbay BK, Reagan DR, Sarubbi FA. 2000. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affairs hospital. Infect Control Hosp Epidemiol 21:459-464. http://dx.doi.org/10.1086/501788.
26. Mongkolrattanothai K, Mankin P, Raju V, Gray B. 2008. Surveillance for mupirocin resistance among methicillin-resistant Staphylococcus aureus clinical isolates. Infect Control Hosp Epidemiol 29:993-994. http://dx.doi.org/10.1086/590536.
27. Jones JC, Rogers TJ, Brookmeyer P, Dunne WM, Jr, Storch GA, Coopersmith CM, Fraser VJ, Warren DK. 2007. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 45:541-547. http://dx.doi.org/10.1086/520663.
28. Simor AE, Stuart TL, Louie L, Watt C, Ofner-Agostini M, Gravel D, Mulvey M, Loeb M, McGeer A, Bryce E, Matlow A. 2007. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 51:3880-3886. http://dx.doi.org/10.1128/AAC.00846-07.
29. Anderson DJ, Podgorny K, Berrios-Torres SI, Bratzler DW, Dellinger EP, Greene L, Nyquist AC, Saiman L, Yokoe DS, Maragakis LL, Kaye KS. 2014. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 35:605-627. http://dx.doi.org/10.1086/676022.
30. Patel JB, Gorwitz RJ, Jernigan JA. 2009. Mupirocin resistance. Clin Infect Dis 49:935-941. http://dx.doi.org/10.1086/605495.
31. Gershenfeld L. 1962. Povidone-iodine as a sporocide. Am J Pharm Sci Support Public Health 134:78-81.
32. Russell AD. 1990. Bacterial spores and chemical sporicidal agents. Clin Microbiol Rev 3:99-119.
33. McLure AR, Gordon J. 1992. In-vitro evaluation of povidone-iodine and chlorhexidine against methicillin-resistant Staphylococcus aureus. J Hosp Infect 21:291-299. http://dx.doi.org/10.1016/0195-6701(92)90139-D.
34. Gottardi W. 1995. The uptake and release of molecular iodine by the skin: chemical and bactericidal evidence of residual effects caused by povidone-iodine preparations. J Hosp Infect 29:9-18. http://dx.doi.org/10.1016/0195-6701(95)90289-9.
35. Houang ET, Gilmore OJ, Reid C, Shaw EJ. 1976. Absence of bacterial resistance to povidone iodine. J Clin Pathol 29:752-755. http://dx.doi.org/10.1136/jcp.29.8.752.
36. Lanker Klossner B, Widmer HR, Frey F. 1997. Nondevelopment of resistance by bacteria during hospital use of povidone-iodine. Dermatology 195(Suppl 2):10-13. http://dx.doi.org/10.1159/000246024.
37. Phillips M, Rosenberg A, Shopsin B, Cuff G, Skeete F, Foti A, Kraemer K, Inglima K, Press R, Bosco J. 2014. Preventing surgical site infections: a randomized, open-label trial of nasal mupirocin ointment and nasal povidone-iodine solution. Infect Control Hosp Epidemiol 35:826-832. http://dx.doi.org/10.1086/676872.
38. Anderson MJ, Scholz MT, Parks PJ, Peterson ML. 2013. Ex vivo porcine vaginal mucosal model of infection for determining effectiveness and toxicity of antiseptics. J Appl Microbiol 115:679-688. http://dx.doi.org/10.1111/jam.12277.
39. Anderson MJ, Horn ME, Lin YC, Parks PJ, Peterson ML. 2010. Efficacy of concurrent application of chlorhexidine gluconate and povidone iodine against six nosocomial pathogens. Am J Infect Control 38:826-831. http://dx.doi.org/10.1016/j.ajic.2010.06.022.
40. Halachmi-Eyal O, Lang Y, Keness Y, Miron D. 2009. Preoperative topical moxifloxacin 0.5% and povidone-iodine 5.0% versus povidone-iodine 5.0% alone to reduce bacterial colonization in the conjunctival sac. J Cataract Refract Surg 35:2109-2114. http://dx.doi.org/10.1016/j.jcrs.2009.06.038.
41. Wu PC, Li M, Chang SJ, Teng MC, Yow SG, Shin SJ, Kuo HK. 2006. Risk of endophthalmitis after cataract surgery using different protocols for povidone-iodine preoperative disinfection. J Ocul Pharmacol Ther 22:54-61. http://dx.doi.org/10.1089/jop.2006.22.54.
42. Casewell MW, Hill RL. 1985. In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 15:523-531. http://dx.doi.org/10.1093/jac/15.5.523.
43. Schenck HU, Simak P, Haedicke E. 1979. Structure of polyvinylpyrrolidone-iodine (povidone-iodine). J Pharm Sci 68:1505-1509. http://dx.doi.org/10.1002/jps.2600681211.
44. Bogataj M, Vovk T, Kerec M, Dimnik A, Grabnar I, Mrhar A. 2003. The correlation between zeta potential and mucoadhesion strength on pig vesical mucosa. Biol Pharm Bull 26:743-746. http://dx.doi.org/10.1248/bpb.26.743.
45. Ko S, Roh YH, Choo JH, Jang SH, Han SH, Jang HG. 2010. Effect of cationic polymer treatment on adhesion of iron oxide to eyelashes. Int J Cosmet Sci 32:314. http://dx.doi.org/10.1111/j.1468-2494.2010.00580-3.x.
46. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, Lankiewicz J, Gombosev A, Terpstra L, Hartford F, Hayden MK, Jernigan JA, Weinstein RA, Fraser VJ, Haffenreffer K, Cui E, Kaganov RE, Lolans K, Perlin JB, Platt R. 2013. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 368:2255-2265. http://dx.doi.org/10.1056/NEJMoa1207290.
47. West SK, Plantenga MS, Strausbaugh LJ. 2007. Use of decolonization to prevent staphylococcal infections in various healthcare settings: results of an Emerging Infections Network survey. Infect Control Hosp Epidemiol 28:1111-1113. http://dx.doi.org/10.1086/519930.
48. Creech CB, Beekmann SE, Chen Y, Polgreen PM. 2008. Variability among pediatric infectious diseases specialists in the treatment and prevention of methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 27:270-272. http://dx.doi.org/10.1097/INF.0b013e31815c9068.
49. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. 2007. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 51:423-428. http://dx.doi.org/10.1128/AAC.01244-06.
50. Engelman R, Shahian D, Shemin R, Guy TS, Bratzler D, Edwards F, Jacobs M, Fernando H, Bridges C, Workforce on Evidence-Based Medicine, Society of Thoracic Surgeons. 2007. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. Ann Thorac Surg 83:1569-1576. http://dx.doi.org/10.1016/j.athoracsur.2006.09.046.
51. Deshpande LM, Fix AM, Pfaller MA, Jones RN. 2002. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis 42:283-290. http://dx.doi.org/10.1016/S0732-8893(01)00328-5.
52. Upton A, Lang S, Heffernan H. 2003. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 51:613-617. http://dx.doi.org/10.1093/jac/dkg127.
53. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. 2002. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 39:337-341. http://dx.doi.org/10.1053/ajkd.2002.30553.
54. Annigeri R, Conly J, Vas S, Dedier H, Prakashan KP, Bargman JM, Jassal V, Oreopoulos D. 2001. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 21:554-559.
55. Watanabe H, Masaki H, Asoh N, Watanabe K, Oishi K, Furumoto A, Kobayashi S, Sato A, Nagatake T. 2001. Emergence and spread of low-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan. J Hosp Infect 47:294-300. http://dx.doi.org/10.1053/jhin.2000.0931.
56. Watanabe H, Masaki H, Asoh N, Watanabe K, Oishi K, Kobayashi S, Sato A, Sugita R, Nagatake T. 2001. Low concentrations of mupirocin in the pharynx following intranasal application may contribute to mupirocin resistance in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 39:3775-3777. http://dx.doi.org/10.1128/JCM.39.10.3775-3777.2001.
57. Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA. 2003. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol 24:342-346. http://dx.doi.org/10.1086/502218.
58. Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, Kiss A. 2007. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 44:178-185. http://dx.doi.org/10.1086/510392.
59. Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D. 2000. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 31:1380-1385. http://dx.doi.org/10.1086/317484.
60. Parenti MA, Hatfield SM, Leyden JJ. 1987. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm 6:761-770.
61. Hodgson JE, Curnock SP, Dyke KG, Morris R, Sylvester DR, Gross MS. 1994. Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870. Antimicrob Agents Chemother 38:1205-1208. http://dx.doi.org/10.1128/AAC.38.5.1205.
62. Antonio M, McFerran N, Pallen MJ. 2002. Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 46:438-442. http://dx.doi.org/10.1128/AAC.46.2.438-442.2002.
63. Block SS (ed). 1991. Disinfection, sterilization, and preservation. Lea & Febiger, Philadelphia, PA.
64. Wilson M, McNab R, Henderson B (ed). 2002. Bacterial disease mechanisms. Cambridge University Press, Cambridge, United Kingdom.